These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 19357103)

  • 1. Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin.
    Adiguzel C; Bansal V; Litinas E; Cunanan J; Iqbal O; Nelson K; Kannan M; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(2):145-51. PubMed ID: 19357103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis.
    Carrier M; Knoll GA; Kovacs MJ; Moore JC; Fergusson D; Rodger MA
    Thromb Res; 2007; 120(2):215-20. PubMed ID: 17098277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG.
    Untch B; Ahmad S; Jeske WP; Messmore HL; Hoppensteadt DA; Walenga JM; Lietz H; Fareed J
    Thromb Res; 2002 Jan; 105(2):117-23. PubMed ID: 11958801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin and oversulfated heparin byproduct induce thrombin generation through contact system activation in plasma of patients with HIT.
    Yi Qian ; Jing Pan ; Xiaodong Zhou ; Weiser P; Hong Lu ; Shih FF; Porche-Sorbet R; Eby C; Lijuan Zhang
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):251-60. PubMed ID: 20460351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical evaluation of assays for detecting antibodies to the heparin-PF4 complex.
    Francis JL
    Semin Thromb Hemost; 2004 Jun; 30(3):359-68. PubMed ID: 15282659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients.
    Kannan M; Saxena R; Adiguzel C; Fareed J
    Semin Thromb Hemost; 2009 Apr; 35(3):337-43. PubMed ID: 19452409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
    Clark M; Hoppensteadt D; Walenga J; Myers L; Cunanan J; Jeske W; Adiguzel C; Iqbal O; Fareed J
    Int Angiol; 2008 Oct; 27(5):370-6. PubMed ID: 18974698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of antiheparin-platelet factor 4 antibodies and heparin-induced thrombocytopenia in Turkish patients undergoing cardiac surgery.
    Demir M; Duran E; Yigitbasi O; Vural O; Kurum T; Yuksel M; Turgut B; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2007 Jul; 13(3):279-84. PubMed ID: 17636189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors for the development of elevated anti-heparin/platelet factor 4 antibody titers in patients undergoing cardiac catheterization.
    Yeh RW; Everett BM; Foo SY; Dorer DJ; Laposata M; Van Cott EM; Jang IK
    Am J Cardiol; 2006 Aug; 98(3):419-21. PubMed ID: 16860036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up.
    Mattioli AV; Bonetti L; Zennaro M; Ambrosio G; Mattioli G
    Am Heart J; 2009 Mar; 157(3):589-95. PubMed ID: 19249435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oversulfated chondroitin sulfate and OSCS-contaminated heparin cause dose- and route-dependent hemodynamic effects in the rat.
    Corbier A; Le Berre N; Rampe D; Meng H; Lorenz M; Vicat P; Potdevin S; Doubovetzky M
    Toxicol Sci; 2011 Jun; 121(2):417-27. PubMed ID: 21436127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
    Ahmad S; Haas S; Hoppensteadt DA; Lietz H; Reid U; Bender N; Messmore HL; Misselwitz F; Bacher P; Gaikwad BS; Jeske WP; Walenga JM; Fareed J
    Thromb Res; 2002 Oct; 108(1):49-55. PubMed ID: 12586132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis.
    Matsuo T; Kobayashi H; Matsuo M; Wanaka K; Nakamoto H; Matsushima H; Sakai R
    Pathophysiol Haemost Thromb; 2006; 35(6):445-50. PubMed ID: 17565238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications.
    Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J
    Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of platelet factor 4-heparin complex antibody (HIT antibody) in the pathogenesis of thrombotic episodes in patients on hemodialysis.
    Nakamoto H; Shimada Y; Kanno T; Wanaka K; Matsuo T; Suzuki H
    Hemodial Int; 2005 Oct; 9 Suppl 1():S2-7. PubMed ID: 16223438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients.
    Ahmad S; Bacher HP; Lassen MR; Hoppensteadt DA; Leitz H; Misselwitz F; Walenga JM; Fareed J
    Arch Pathol Lab Med; 2003 May; 127(5):584-8. PubMed ID: 12708902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products.
    Bairstow S; McKee J; Nordhaus M; Johnson R
    Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency of antibodies directed against heparin-platelet factor 4 in patients exposed to heparin through chronic hemodialysis.
    de Sancho M; Lema MG; Amiral J; Rand J
    Thromb Haemost; 1996 Apr; 75(4):695-6. PubMed ID: 8743204
    [No Abstract]   [Full Text] [Related]  

  • 19. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin.
    McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R
    J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved laboratory confirmation of heparin-induced thrombocytopenia type II. Time course of antibodies and combination of antigen and biologic assays.
    Harenberg J; Wang L; Hoffmann U; Huhle G; Feuring M
    Am J Clin Pathol; 2001 Mar; 115(3):432-8. PubMed ID: 11242800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.